IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying
Portfolio Pulse from Lisa Levin
Insiders at VolitionRx, KORE Group Holdings, and IO Biotech have recently made notable stock purchases. VolitionRx Director Guy Archibald bought 20,000 shares at $0.71 each, while EF Hutton reiterated a Buy rating with a $4.5 target. KORE CEO Romil Bahl acquired 12,514 shares at $0.62 each, despite the company's Q3 results missing estimates and a lower FY23 revenue guidance. IO Biotech's Chief Accounting Officer Brian Burkavage purchased 10,000 shares at $1.01 each after the company reported a narrower-than-expected quarterly loss.
November 27, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
KORE CEO Romil Bahl bought 12,514 shares despite recent poor Q3 results and lower FY23 guidance, indicating potential undervaluation.
The CEO's purchase might counterbalance the negative sentiment from poor Q3 results and lower guidance, but the impact on the stock price is uncertain.
CONFIDENCE 65
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
IO Biotech's Chief Accounting Officer Brian Burkavage bought 10,000 shares after a narrower-than-expected quarterly loss, suggesting optimism.
The insider purchase following a better-than-expected earnings report could be seen as a positive sign, potentially leading to a short-term uptick in the stock price.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
VolitionRx Director Guy Archibald purchased 20,000 shares, signaling insider confidence. EF Hutton maintains a Buy rating with a $4.5 target.
Insider purchases often signal confidence in the company's prospects, and the reiteration of a Buy rating by EF Hutton could positively influence the stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90